Corvus Pharmaceuticals (NASDAQ:CRVS) shareholders have done very well over the last year, with the share price soaring by 226%. However, only a fool would ignore the risk that a loss making company burns through its cash too quickly. In this report, we will consider the company's annual negative cash flow, henceforth referring to it as the 'cash burn'